Last reviewed: June 4, 2026
Last updated: June 4, 2026
Written by:
Jay Hastings,
CEO of PlexusDx
Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.
Medically reviewed by:
Jayden Lee, PharmD, EMBA
Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.
This article is part of the PlexusDx Education Hub — science-backed guidance on GLP-1 medications, metabolic health, and precision weight management.
Type 1 diabetes management has traditionally focused on insulin control, but emerging research shows that GLP-1 receptor agonists can address both blood sugar regulation and weight loss simultaneously. Studies indicate that approximately 40% of type 1 diabetes patients struggle with weight gain, a challenge that standard insulin therapy alone often cannot resolve. PlexusDx provides access to compounded GLP-1 medications designed to support your unique metabolic needs.
How GLP-1 Agonists Work in Type 1 Diabetes Management
GLP-1 receptor agonists function by mimicking glucagon-like peptide-1, a hormone that regulates blood sugar and appetite. In type 1 diabetes, these medications work alongside insulin therapy by slowing gastric emptying, which allows for more gradual glucose absorption and reduces post-meal blood sugar spikes. This dual action helps reduce the total daily insulin dose many patients require, creating a synergistic effect that addresses both glucose control and body weight.
Beyond blood sugar management, GLP-1 agonists activate receptors in the brain's appetite control centers, signaling fullness and reducing hunger-driven eating patterns. This mechanism differs fundamentally from insulin alone, which can paradoxically increase appetite and promote weight gain. For type 1 diabetes patients, this combination means better metabolic stability without the weight burden that often accompanies intensive insulin regimens.
Clinical Evidence Supporting GLP-1 Use in Type 1 Diabetes
Recent clinical trials have demonstrated meaningful weight reduction in type 1 diabetes populations treated with GLP-1 agonists. A landmark study showed that patients receiving semaglutide alongside insulin experienced average weight losses of 3-5 kg over 16 weeks, while maintaining or improving hemoglobin A1C levels. These results suggest that GLP-1 therapy addresses a critical gap in type 1 diabetes care: achieving weight loss without compromising glycemic control.
Research also indicates that GLP-1 agonists reduce the risk of diabetic complications related to excess weight, including cardiovascular disease and kidney dysfunction. The cardiovascular benefits observed in type 2 diabetes populations are increasingly recognized in type 1 patients as well, making GLP-1 therapy a comprehensive metabolic intervention rather than a standalone weight loss tool. PlexusDx's approach incorporates this evidence-based foundation into personalized treatment plans.
Semaglutide Injection for Type 1 Diabetes Weight Management
PlexusDx compounded semaglutide injection offers a practical, affordable entry point into GLP-1 therapy, starting at $149 per month with no insurance requirement. Semaglutide is administered once weekly, providing consistent blood levels and reducing the medication management burden compared to daily oral formulations. For type 1 diabetes patients already managing multiple daily insulin injections, the single-weekly semaglutide dose integrates seamlessly into existing treatment routines.
The compounded semaglutide delivered through PlexusDx comes from licensed 503A pharmacies, ensuring quality and safety standards equivalent to brand-name medications at a fraction of the cost. Your dose may need to go up as you progress through treatment, but PlexusDx maintains flat monthly pricing across all dosing levels, eliminating surprise costs as your therapy advances. Patients can access this medication in all 50 states without waiting for insurance approval.
Personalization Through Genetic Insights and PlexusDx Testing
Type 1 diabetes patients vary significantly in how they respond to GLP-1 therapy, differences that often trace back to genetic variations in peptide pathways. PlexusDx's Precision Peptide Genetic Test identifies key genetic markers including GLP1R rs6923761, GIPR rs1800437, FTO rs9939609, and MC4R rs17782313, which directly influence how your body responds to semaglutide and other GLP-1 agonists. This test maps 14 metabolic pathways and 150+ genetic insights specific to weight management and appetite regulation.
Understanding your genetic profile allows PlexusDx to tailor semaglutide dosing strategies and predict which patients may benefit from dual-compound therapy like GLP-Squared injection. The Precision Peptide Genetic Test is available as a $99 add-on after your first month of treatment, providing actionable data that transforms weight management from trial-and-error to precision medicine. Patients who understand their genetic predispositions often achieve faster results and experience fewer unexpected side effects.
Managing Side Effects and Expectations in Type 1 Diabetes Treatment
Common GLP-1 side effects include mild nausea, constipation, and diminished appetite during the initial weeks of therapy. These effects typically resolve within 2-4 weeks as your body adjusts, and they generally indicate the medication is working as intended. Type 1 diabetes patients should monitor blood sugar closely when starting semaglutide, as improved insulin sensitivity often requires reductions in daily insulin doses to prevent hypoglycemia.
PlexusDx recommends working closely with your diabetes care team to adjust insulin regimens as semaglutide takes effect. The reduced insulin requirement—often 15-30% lower within the first month—reflects improved metabolic function rather than disease progression. HSA and FSA accounts can cover PlexusDx compounded semaglutide, making personalized GLP-1 therapy financially accessible for most patients.
How Your Genetics Influence GLP-1 Response
Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month of treatment) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.
Access Personalized GLP-1 Care Through PlexusDx
PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Semaglutide Injection starts at $149/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.
Frequently Asked Questions
Can I use semaglutide if I have type 1 diabetes and currently take insulin?
Yes, semaglutide from PlexusDx is specifically designed to complement insulin therapy in type 1 diabetes. However, you must work with your healthcare provider to adjust insulin doses as semaglutide improves your body's glucose utilization.
How much weight can I realistically expect to lose with GLP-1 therapy?
Clinical data shows type 1 diabetes patients typically lose 3-5 kg in the first 16 weeks of semaglutide treatment, with cumulative weight loss continuing over 6-12 months. Individual results vary based on genetics, diet, exercise, and insulin management.
Why is PlexusDx semaglutide so affordable compared to brand-name options?
PlexusDx partners with licensed 503A compounding pharmacies to manufacture high-quality semaglutide at lower costs than brand-name manufacturers. Starting at $149 per month with no insurance required, PlexusDx passes savings directly to patients while maintaining safety and efficacy standards.
Are compounded GLP-1 medications from PlexusDx safe for type 1 diabetes?
Yes, PlexusDx compounded medications come exclusively from licensed 503A pharmacies that follow FDA standards for safety and purity. While not FDA-approved as branded drugs, compounded semaglutide and tirzepatide are legal, medically supervised options widely prescribed by endocrinologists for type 1 and type 2 diabetes.
Should I get the Precision Peptide Genetic Test if I have type 1 diabetes?
The Precision Peptide Genetic Test is valuable for type 1 diabetes patients because it identifies genetic variations (like GLP1R rs6923761 and MC4R rs17782313) that predict your response to semaglutide and other GLP-1 agonists.
Related Reading
Pricing and availability current as of June 2026. Compounded GLP-1 medications are not FDA-approved drug products; they are prepared by licensed compounding pharmacies under federal compounding regulations. Compounded semaglutide and tirzepatide are not the same as Wegovy, Ozempic, Zepbound, or Mounjaro. This article is for informational purposes only and does not constitute medical advice. Consult a licensed healthcare provider before starting, stopping, or changing any medication.
Return to the PlexusDx Education Hub for more evidence-based resources on GLP-1 therapy, metabolic health, and personalized weight management.
Medical and Editorial Standards
Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.
Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.
Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.
Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.
Share:
Does Mounjaro Help Hormones? A Detailed Look at Tirzepatide and Metabolic Health
Can You Take 2 GLP-1 Together? Exploring the Possibilities and Considerations